A study to evaluate the immunogenicity, safety and reactogenicity of adjuvanted influenza vaccine candidates compared to Fluarix administered intramuscularly in subjects aged 18−59 years.

Trial Profile

A study to evaluate the immunogenicity, safety and reactogenicity of adjuvanted influenza vaccine candidates compared to Fluarix administered intramuscularly in subjects aged 18−59 years.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs GSK 1247446A (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Feb 2007 Status change
    • 14 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top